All posts by imreal

EvidenceCare Announces Launch of Admission Criteria Solution Driving Real ROI through Clinical Decision Support Technology


Carol Howard

EvidenceCare, a leading provider of advanced clinical decision support (CDS) technology, today announced the launch of its innovative Admission Criteria solution expanding the company’s CDS platform to create real impact on the hospital revenue cycle by ensuring accurate admission documentation to proactively address a significant source of denials. The company is also announcing the addition of Carol Howard as vice president of clinical content, an industry expert on the clinical aspects of the revenue cycle.

The Admission Criteria solution, developed in partnership with MCG Health, enables a clinically driven revenue cycle by incorporating evidence-based admission criteria to properly determine and document bed status at the time of admission. The solution offers significant financial return for hospitals based on inappropriate bed status, determinations, and denials due to insufficient documentation.

To support both content and business development efforts, Carol Howard offers a unique blend of clinical and revenue cycle experience to add to the EvidenceCare team. As a registered nurse with extensive background in decision support, denials, utilization and revenue management, she will leverage her deep knowledge base to lead the ongoing development and support of the Admission Criteria solution.

“Emergency Departments (ED) are the front door of the hospital. They face the daunting challenge of making split-second decisions and deserve immediate access to updated medical research to ensure the best clinical outcome for patients,” said Dr. Brian Fengler, chief executive officer and co-founder of EvidenceCare. “We are thrilled to have Carol join the team and apply her front-line nursing experience and revenue cycle expertise to the launch of the Admission Criteria solution. With Carol’s leadership, we will enable frontline providers to deliver effective, efficient, and evidenced-based care.”

“Clinicians drive the revenue cycle through accurate documentation. Too often, we address denials after the fact when a proactive approach could address up to 60% of denials,” said Carol Howard, vice president, clinical content of EvidenceCare. “I am looking forward to becoming an integral part of the forward-thinkers at EvidenceCare that seek creative solutions to help hospitals remain solvent, especially given the impact of the pandemic, so that they might continue to deliver excellent care in the communities they serve.”

About EvidenceCare

EvidenceCare is the leading clinical decision support system (CDSS) driving real ROI. Founded in response to the professional experience of emergency physician Dr. Brian Fengler, the platform is integrated into a clinician’s EHR workflow, delivering customized, interactive, curated guidance directly into the care process. With EvidenceCare, hospitals, emergency departments and urgent care centers enable clinicians to deliver evidence-based care with measurable outcomes. Through advanced CDSS technology, variance is reduced, and the appropriate criteria are documented during utilization and admission decisions. With government-mandated compliance measures and quality program initiatives achieved, healthcare organizations ensure that quality and safety improve, liability is reduced, and operational efficiency is increased while capturing additional revenue. To learn more, visit http://www.evidence.care or follow us on Twitter @evidencecare or LinkedIn.

About MCG Health

MCG, part of the Hearst Health network, helps healthcare organizations implement informed care strategies that proactively and efficiently move people toward health. MCG’s transparent assessment of the latest research and scholarly articles, along with our own data analysis, gives patients, providers, and payers the vetted information they need to feel confident in every care decision, in every moment. For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

Share article on social media or email:



Luminec Pharmaceuticals Submits New Evidence for NIH, BARDA Coronavirus Application


Dr. Susana Alcázar-Leyva

Based on these new studies, we believe that X-2 and CRO-50 can make a significant contribution in the treatment of the novel Coronavirus.

As part of its application for consideration to the National Institute of Allergies and Infectious Diseases (NIAID) and to the Biomedical Advanced Research and Development Authority (BARDA), Luminec Pharmaceuticals is submitting new case studies showing strong evidence of the efficacy of our combined therapy of CRO-50 (ribonuclease) and X-2 (stable thiamine formulation) in COVID-19 patients, as well as in other Coronavirus patients.

These case studies were compiled by Luminec Executive Board Member Susana Alcázar-Leyva, MD, PhD, based on her first-hand experience with patients around the world. According to Dr. Alcázar-Leyva, “Based on these new studies, we believe that X-2 and CRO-50 can make a significant contribution in the treatment of the novel Coronavirus.”

In addition to her role with Luminec Pharmaceuticals, Dr. Alcázar-Leyva is a founding director of the prestigious Hans Selye Scientific Research Institute, and cofounder and director of the Heberto Alcázar-Montenegro Gerontology School (cofounded by, and named for, her father), and of the Albert Szent-Györgyi Gerontology Center.

Stephen Holt, MD, DSc, PhD, Luminec chief science officer, commented, “We are presenting Dr. Alcázar-Leyva’s findings to BARDA and NIAID to support our application in the hopes that our protocols will be cleared for a regulatory pathway to FDA approval.” Dr. Holt noted that Luminec Pharmaceuticals is also making a similar submission to the Israel National Institute for Health Policy Research (NIHP) for consideration in their battle with the Coronavirus.

About Luminec Pharmaceuticals

Headquartered in Carlsbad, CA, Luminec Pharmaceuticals currently offers a unique array of all-natural OTC products and clinical services for both human and animal use. Luminec’s products include natural proprietary formulations based on the Schutt Paradigm of Free Amino Ion Alignment & Molecular Stability, in combination with proprietary partner technologies with a cutting edge delivery technology, oral and topically, composed of charged delivery spheres that encapsulate and transport active compounds into the system, naturally.

Luminec Pharmaceuticals is a wholly owned subsidiary of Luminec Holding Corporation, a private company.

Share article on social media or email:

Cinera Edge, an Immersive 5K Personal Movie Theater Headset with Dolby Digital Surround Sound, Launches on Kickstarter


News Image

Cinera offers a truly theatrical experience with the most advanced video and audio technology, so movie lovers can enjoy a cinematic film anywhere, anytime.

Cinera Edge, the world’s first Head Mount Display (HMD) with dual 2.5K micro OLED and Dolby Digital certified 5.1 surround sound headphones, today launched on Kickstarter.

Cinera is the first true mobile cinema that delivers a real theatrical immersive experience with extraordinary video and sound quality.

After a successful crowdfunding campaign in 2017 that raised over $300,000, the Cinera team collected positive feedback from those backers to improve on the design and features for this latest version. The sequel will feature micro-OLED that packs 3.7 million (2560×1440) pixels into a tiny 0.83-inch screen that transforms into a 120-inch movie screen experience with certified Dolby Digital 5.1 channel surround sound headphones.

Cinera, which combines Cine + Era for its vision of the future of movie cinemas, runs on a full Android OS and can be used with today’s popular streaming apps via Wi-Fi with no need for an external device.

“We are in a new era of cinema when visiting a movie theater is not always convenient or safe,” said Peter Lin, founder of Cinera, who previously worked in the digital movie industry, offering technical solutions to movie theatres. “Cinera offers a truly theatrical experience with the most advanced video and audio technology, so movie lovers can enjoy a cinematic film anywhere, anytime.”

Cinera’s screen is as large as 1200″ from a 20m distance or 66-degree wide horizontally, wider than a standard 54-degree cinema screen and nearly as wide as IMAX’s signature 70-degree screen.

Cinera Edge is Dolby Digital certified so it can process high resolution audio without quality degrade. With four speaker drivers at each side, Cinera Edge recreates 5.1 surround sound configuration as in a movie theater.

“Part of movies’ magic comes from the theaters’ big screen and vivid sound, that’s why movies don’t always feel right on TV or mobile phones,” added Lin. “We are working hard to bring this cinematic experience beyond movie cinemas.”

Cinera’s smart design focuses the weight on the two sides, leaving less pressure in the front pieces and on the user. With an ergonomically designed body, Cinera Edge is easy to wear comfortably for many hours.

While it was designed for movies, Cinera can also be connected with a HDMI cable to play video games, watch sports and TV shows, pilot drones, and use it on a PC. Cinera also features a micro SD card for users to bring their favorite content with them when traveling.

For more information and to pre-order the Cinera Edge at early-bird discounts, visit the crowdfunding page on Kickstarter.

About Cinera – Cinera was founded in 2016 by a group of movie fans who are passionate about movies, technology and elegant product design. The Cinera team successfully launched their first-generation product – a 5K Head Mounted Display in 2017 on Kickstarter and raised over $300K from more than 600 backers on Kickstarter and Indiegogo. In 2020, Cinera announced its sequel – an HMD with the latest micro OLED technology with 2560×1440 pixels in a 0.83-inch area. Cinera Edge also has an embedded Dolby Digital certified 5.1 surround sound headphone.

Share article on social media or email:

Flagship Biosciences Launches New Clinical Diagnostics Service


Flagship Biosciences, Inc. Logo

Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients.

Flagship Biosciences, providers of expert tissue data insights, today announced that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight. TissueInsight provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment (TME).

“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” said Trevor Johnson, Flagship CEO. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”

Flagship’s exclusive, targeted testing in its College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab delivers the highly accurate tissue scoring needed for precision medicine. Combined with its award-winning technology and sign-off from its experienced pathologists for every client, TissueInsight gives rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring. Along with its CLIA-reportable results, TissueInsight TME data includes information on tumor infiltrating lymphocytes (TILs) and macrophages.

“I’m extremely pleased to bring this new clinical diagnostics service to the market,” said Johnson. “Flagship’s scientific process, machine learning, and laboratory capabilities are enabling us to work with clinicians to expand immuno-oncology diagnostic tissue tests that will make their work more efficient and better help them to deliver on the promise of precision medicine for their patients.”

About Flagship Biosciences

Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. It is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Flagship’s services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability and bringing new insights to tissue analysis results. With expert scientific consultation for every client, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success. flagshipbio.com

For more information please contact Pamela Curran of Stratos Global Marketing, at pam@stratosglobalmarketing.com or +1 (303) 818 9316.

Share article on social media or email:

Suppliers Have Embraced Electronic Invoicing & Payments During COVID-19


Suppliers serving real estate companies have forgone paper invoices and checks, and substantially increased their adoption of electronic delivery methods during this pandemic, according to a new study by Nexus, the leading AP automation company for real estate.

During the months of March, April, and May 2020, suppliers increased their usage of NexusConnect, an online portal to submit invoices to buyers by 15 percent, even while purchasing shrank precipitously.

They also increased their acceptance of electronic payment methods – Nexus virtual cards in particular – by an average of 42% a month for each of the three months, compared to the same months in 2019.

“We are seeing a real transformation in supplier behavior,” said Jennifer Coolidge, Nexus president and head of the supplier program.

She noted several factors are at work:

  • Working from Home: Suppliers, like buyers, are working from home, and they don’t want to – or can’t – go into the office to send invoices/receive checks.
  • Cash Flow Concerns: Many buyers are not able to cut checks every week, but they are able to submit electronic payments every week (or even more frequently if need be). So suppliers have opted for electronic methods, like virtual cards, in order to get paid. In fact, many have become “network acceptors” to receive virtual cards for all their payments.
  • Greater Visibility: Electronic delivery offers real-time visibility/transparency that paper methods simply can’t provide because of mail float.


This uptick in digital invoices and payments came at the time the country’s economy contracted significantly and purchasing was down overall.

Real estate has been no exception. For example, electronic purchase orders issued through the Nexus platform were down 77% for make-ready purchases (paint, carpet, and other purchases to make units ready for the next tenant) for the period of March-May 2020, compared to the prior year.

Coolidge said a lot of suppliers shifted their invoice submissions to NexusConnect because the portal provides guaranteed invoice delivery – which they don’t enjoy with the U.S. mail service. It also provides suppliers with real time status about whether invoices have been received, approved, paid, or rejected.

“Online visibility is exceptionally important in times like these, since there’s often no one in the office to take a call,” she said.

In addition, suppliers opted for electronic virtual cards, over receiving paper checks, as part of the NexusPayments program, wherein Nexus pays suppliers on behalf of its clients.

Nexus data shows that monthly acceptance rates of virtual cards went up 56% in March, 38% in April, and 45% in May, compared to the prior year.

While the terms of Nexus virtual cards didn’t change, more suppliers opted into them because they wanted guaranteed funds, greater security, and faster payment, said Director of Supplier Solutions Lisa Hills.

The Nexus AP automation platform is designed specifically for real estate companies, which need to process high volumes of invoices every month from a broad range of suppliers, from the one-person landscaping company to the multi-billion-dollar retail store.

With just a few clicks, Nexus customers can upload invoices, compare them to budget, route them to approvers, and then submit them for payment. They can also authorize Nexus to pay their suppliers with virtual card, ACH, or check.

Suppliers, meanwhile, can use Nexus to connect to their buyers and transact with them securely, all with unparalleled visibility into their transactions.

One in five of the world’s largest real estate companies use the Nexus AP automation platform to automate accounts payable and control their spend.

About Nexus

With Nexus Procure-to-Pay software, real estate companies can manage every aspect of the accounts payable process – from purchase through payments – with just a few clicks. The web-based platform automates manual AP tasks and provides complete visibility into suppliers, budgets, and spend. No more paper, wasted time, nor guesswork. Nexus makes it easy to maintain and expand the supplier relationships at the heart of the real estate business. Visit http://www.Nexussystems.com.

Share article on social media or email:

State Veterinary Medical Associations Endorse FELINE FIX BY FIVE MONTHS as best practice


News Image

STATE VETERINARY MEDICAL ASSOCIATIONS ENDORSE FELINE FIX BY FIVE MONTHS AS BEST PRACTICE

Following the lead of the American Veterinary Medical Association, the American Animal Hospital Association, and the American Association of Feline Practitioners, state veterinary medical associations in Maine, Arkansas, Kentucky and Mississippi have formally endorsed the best practice of spaying or neutering cats before five months of age.

“When state veterinary associations embrace and endorse the recommended best practice of spaying and neutering cats by five months of age, it amplifies our message that the benefits of ‘fixing by five months’ are numerous and impactful to the health and welfare of cats, and to the problem of overpopulation in communities across the country and around the world,” said Feline Fix by Five’s Program Director, Esther Mechler.

Historically, the recommended age for spaying and neutering cats was six months. However, the benefits of performing surgery earlier not only result in faster recovery and fewer unwanted litters, but also health and behavioral benefits that can help reduce the number of cats relinquished to shelters by their owners.

  • The risk for mammary cancer (which is fatal in over 85% of diagnosed cases) in female cats who are spayed before their first estrous cycle is reduced by 91%.*
  • Neutering male cats reduces many undesirable behaviors such as urine marking, aggressive behavior and roaming behaviors which can result in serious injuries, diseases and death.
  • Cats sterilized before puberty are less likely to exhibit undesirable behaviors secondary to sex hormones. This also makes it more likely for cats to remain with their owners long term since many cats are surrendered to shelters due to these undesirable behaviors.

“Cat owners who may be unsure of when to spay or neuter their pet, or who wait until they are six months of age, are often faced with the dilemma of what to do with an unexpected litter of kittens. Ironically, the problem is not always the result of owners refusing to spay or neuter their cat – they simply did not know that performing the surgery before a cat reaches sexual maturity has benefits beyond just preventing ‘surprise’ litters,” said Dr. Philip Bushby, DVM, MS, DACVS, veterinary medical advisor to the Fix by Five Months campaign.

Since the Feline Fix by Five Months campaign was launched in 2016, the boards of all major national veterinary organizations and many national cat-welfare organizations have formally endorsed the practice of Fixing by Five Months.

About Feline Fix by Five Months

Feline Fix by Five Months is an initiative of Marian’s Dream, a non-profit organization that provides support to animal welfare groups and organizations dedicated to bringing awareness to animal welfare issues. The campaign’s mission is to educate veterinarians, the general public and cat owners on the medical, behavioral and community benefits of spaying and neutering cats before the age of five months. For more information, visit http://www.FixByFive.org

*”Mammary Tumors” Cornell Feline Health Center. Accessed June 2020.

FOR INFORMATION

Becky Price

860-706-2667

ctyankeeinmidwest@gmail.com

Share article on social media or email:

The HeroZona Foundation Launches Free COVID-19 Drive-Thru Testing


With Arizona seeing one of the highest COVID-19 surges in the country at 74,000 confirmed cases, continued testing remains critical. In an effort to help slow the spread of the disease, the HeroZona Foundation has partnered with SRP, the Travis L. Williams American Legion Post 65, Maricopa County’s District 5 and the Arizona Chamber of Commerce and Industry to offer free drive-thru COVID-19 testing at South Mountain Community College (7050 S. 24th St.) in Phoenix on Thursday, July 2; Friday, July 3; Thursday, July 9 and Friday, July 10 from 8 a.m. to 6 p.m.

“This effort is critically important to help provide testing for Arizonans in the South Phoenix communities,” said President & CEO of the Arizona Chamber of Commerce and Industry, Glenn Hamer. “There has been a spike in cases and this additional testing is needed now. I have a deep appreciation for Alan “AP” Powell, Founder of the HeroZona Foundation, for brining the additional testing sites to our state where it’s needed the most. The Arizona Chamber of Commerce and Industry strongly support this effort.”

The testing will be conducted by Lab24, a family owned business located in South Florida that operates nationally with a focus in molecular testing. There is no pre-registration or appointment necessary to get tested at the community event and tests will be available until supplies run out. Those who wish to get tested must have a valid ID.

“Additional testing is needed immediately in South Phoenix to keep our communities safe,” said HeroZona Foundation Founder and U.S. Army Desert Storm Veteran, Alan “AP” Powell. “We created this event to help bring additional testing sites to areas that need it the most.”

Those attending do not need to have symptoms present to be tested and the test will only check for viral symptoms, not antibodies.

“We are happy to have the opportunity to help support all of our communities in an effort to contain the Coronavirus through much needed testing,” said Territory Manager for Lab24, Marsha Wood. “Our goal with Covid-19 testing is to partner with community organizations, religious organizations, and clinics that support the undeserved population.”

The event is supported by SRP, Roosevelt Elementary School District 66, Phoenix Union High School District, Arizona State Conference NAACP, Greater Phoenix Urban League, 100 Black Men Phoenix, African American Christian Clergy Coalition, Mega 104.3 and 101.1 The Beat.

“SRP appreciates the opportunity to support this important effort,” said SRP Chief Public Affairs Executive Rob Taylor. “We are at a juncture where testing for COVID-19 across all populations is critical and we are hopeful this event will help slow the spread of the virus and further protect the communities we serve.”

“I’m proud to be part of this partnership between government, public, private and non-profit groups to serve our community in getting more testing for our residents,” said Maricopa County Supervisor for District 5, Steve Gallardo. “Along with testing, we must continue to be vigilant in wearing masks in public, practicing social distancing and frequent hand washing.”

For more information about the HeroZona Foundation and all of its programs, visit herozona.org.

About HeroZona Foundation

The mission of HeroZona Foundation is to create and empower Heroes in Phoenix communities. The HeroZona Foundation’s annual HeroZona National Veteran Summit created a multi-day networking experience to improve America’s support of veteran companies through workshops, networking, entrepreneurial connections, and seminars. The summit will return to Arizona for a fourth year in November 2020. Other programs include the Bridge Forum, Phoenix Tools 4 School, Play it Forward, Honor Walk, Veterans Reach to Teach, Voting for Veterans and Play It Forward. For more information, visit herozona.org

Share article on social media or email:

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer’s Patients


We found indications of higher iron deposition in the deep gray matter and total neocortex, and regionally in temporal and occipital lobes, in Alzheimer’s disease patients compared with age-matched healthy individuals.

Researchers using MRI have found that iron accumulation in the outer layer of the brain is associated with cognitive deterioration in people with Alzheimer’s disease, according to a study published in the journal Radiology.

Alzheimer’s disease is a progressive type of dementia that impairs and eventually destroys memory and other brain functions. There is no cure, although some treatments are thought to slow the progression.

Previous research has linked abnormally high levels of iron in the brain with Alzheimer’s disease. Iron deposition correlates with amyloid beta, a protein that clumps together in the brains of people with Alzheimer’s disease to form plaques that collect between neurons and disrupt cell function. Associations have also been found between iron and neurofibrillary tangles, abnormal accumulations of a protein called tau that collect inside neurons. These tangles block the neuron’s transport system, which harms the communication between neurons.

It is known that deep gray matter structures of patients with Alzheimer’s disease contain higher brain iron concentrations. Less is known about the neocortex, the deeply grooved outer layer of the brain that is involved with language, conscious thought and other important functions. The neocortex is challenging to assess by MRI, as the anatomy of the area makes MRI prone to distortions, signal decays and artifacts.

“The best solution to minimize these artifacts would be using ultra-high-resolution scans,” said study coauthor Reinhold Schmidt, M.D., professor of neurology and chairman of the Department of Neurology at the Medical University of Graz in Graz, Austria. “However, in the clinical setting, scan time is a limiting factor, and a compromise has to be found.”

For the new study, Dr. Schmidt and colleagues developed an approach using a 3T MRI scanner that allowed the best tradeoff between resolution and scan time, along with postprocessing to correct the influence of the distortions.

They used the MRI system to investigate baseline levels of brain iron in 100 individuals with Alzheimer’s disease and 100 healthy controls. Of the 100 participants with Alzheimer’s disease, 56 had subsequent neuropsychological testing and brain MRI at a mean follow-up of 17 months.

The technique enabled the researchers to create a map of brain iron, determining iron levels in parts of the brain like the temporal lobes, or the areas of the brain lying underneath the temples, and the occipital lobes in the back of the head.

“We found indications of higher iron deposition in the deep gray matter and total neocortex, and regionally in temporal and occipital lobes, in Alzheimer’s disease patients compared with age-matched healthy individuals,” Dr. Schmidt said.

The brain iron accumulation was associated with cognitive deterioration independently of brain volume loss. Changes in iron levels over time in the temporal lobes correlated with cognitive decline in individuals with Alzheimer’s disease.

“These results are all in keeping with the view that high concentrations of iron significantly promote amyloid beta deposition and neurotoxicity in Alzheimer’s disease,” Dr. Schmidt said.

The results point to a potential role in Alzheimer’s disease treatment for drugs that reduce the iron burden in the brain. These drugs, known as chelators, can remove excess iron from the body.

“Our study provides support for the hypothesis of impaired iron homeostasis in Alzheimer’s disease and indicates that the use of iron chelators in clinical trials might be a promising treatment target,” Dr. Schmidt said. “MRI-based iron mapping could be used as a biomarker for Alzheimer’s disease prediction and as a tool to monitor treatment response in therapeutic studies.”

###

“Cross-sectional and Longitudinal Assessment of Brain Iron Level in Alzheimer Disease using 3-T MRI.” Collaborating with Dr. Schmidt were Anna Damulina, M.D., Lukas Pirpamer, M.Sc., Martin Soellradl, M.Sc., Maximilian Sackl, M.Sc., Christian Tinauer, M.Sc., Edith Hofer, Ph.D., Christian Enzinger, M.D., Benno Gesierich, Ph.D., Marco Duering, M.D., Stefan Ropele, Ph.D., and Christian Langkammer, Ph.D.

Radiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on brain MRI, visit RadiologyInfo.org.

AWATfit Rocks the Fitness Industry With New Franchise Concept


In the two short years since fitness enthusiast and entrepreneur Rich Decker founded his mobile fitness concept, AWATfit (Any Where Any Time Fitness), the business has seen explosive success in its home market of Long Island, and that was before the coronavirus pandemic forced consumers to rethink how and where they exercise. Now, fitness-oriented entrepreneurs across the country have the opportunity to replicate Decker’s success for themselves with AWATfit’s new franchise model.

AWATfit may be a young company, but Decker leveraged more than 30 years of experience in the industry to build the concept, and the business’s early success reflects a deliberate strategy to disrupt a stagnant fitness marketplace and grow fast.

“I’ve done the brick-and-mortar thing, and I got sick of it,” Decker said. “The whole industry hasn’t changed in decades even though more people are working out than ever before. I saw a big opportunity there.”

AWATfit’s primary innovation is providing outdoor workouts for clients, the demand for which Decker says unites just about everyone who has ever lifted a barbell.

“Whether you’re a professional athlete or just trying to get some exercise in after work, the one thing that everyone hates about going to the gym is the environment — running in place, staring at walls, and now germs. When you exercise outdoors, your energy and mood increase automatically, but most people don’t have access to a full set of gym equipment outside.”

AWATfit offers just that, bringing a fully loaded mobile gym built out of the back of a 20-foot pickup truck directly to clients, whether that’s at their homes, the beach, a playing field or anywhere else.

And AWATfit is not a seasonal business. Decker says he’s worked with clients in as low as 12-degree weather. In fact, AWAT originally stood for All Weather, All Terrain, but Decker changed that to Any Where, Any Time to make the concept less intimidating to more novice clients. “It’s invigorating to exercise outdoors in the winter, and our clients are excited to have the opportunity,” Decker said.

On top of providing an innovative, outdoor workout experience for clients, AWATfit’s trucks also provide profound benefits for Decker and any future AWATfit owners. By eliminating the brick-and-mortar element of gym ownership, AWATfit dramatically slashes overhead and organically expands the brand’s marketing footprint. Plus, franchise owners can be up and running within a month’s time.

“I’ll be parked in a parking lot and people will take pictures of the truck,” Decker said. “It’s a billboard you can’t pay for. I’ve never had to spend millions on rent and advertising to promote this business. All I’ve got is a really cool website, a social media presence and a 20-foot truck.”

AWATfit’s trucks are poised to “blow away the brick-and-mortar gym industry,” Decker says. “My youngest client is 10 years old, and my oldest is 86. That’s a range you are not going to see at traditional gyms. We can reach a larger client base because we come to them, and because our services are fully customizable.”

Decker expects to have little trouble finding franchisees to take his business to new markets across the country. “I’m already fielding calls every day,” he said. “People want to know how they can get their own truck and start doing business.” And that’s not just in Long Island. Decker has already gotten inquiries from prospective owners as far away as Bogota, Columbia and Australia.

“This is an incredibly attractive prospect for someone in the fitness industry who wants to own their own business,” Decker said. “There are a lot of fantastic trainers out there who don’t have a lot of management experience, and we’ve essentially packaged up a business for them so they can hit the ground running without taking a million classes or going through a giant learning curve.”

Decker plans to make the most of that eager interest from prospective franchisees, aiming to onboard up to 1,000 new franchisees in markets like California, Colorado, Florida and Michigan. And because operational costs to run the business are so low, new franchisees can get started with a modest investment. After that, they’re taking ninety cents on the dollar.

As for just who Decker is looking to bring on board, he says the qualifications are simple:

“The ideal AWATfit franchisee is anybody who loves fitness and being around people,” he said. “There’s not much else to it. If you know your way around exercise equipment and you like to work with people, this is your shot at getting rich doing what you love to do.”

To learn more about franchising with AWATfit, visit https://www.awatfit.com/franchise/.

Share article on social media or email:

3D Ultrasound Enables Accurate, Noninvasive Measurements of Blood Flow


We had less than 10% error or variation. For some of the systems, we were down to only 3% to 5% difference between labs. These are fantastic results that show that, from a technology point of view, some systems could be ready to go to the clinic.

A 3D ultrasound system provides an effective, noninvasive way to estimate blood flow that retains its accuracy across different equipment, operators and facilities, according to a study published in the journal Radiology.

Measures of blood flow are important in helping clinicians determine how much oxygen and nutrient-carrying blood is reaching organs and tissues in a patient’s body. In emergency situations, accurate blood flow measurements can show if there is adequate blood supply to organs like the heart and brain. Blood flow measurements are important in chronic conditions too, as in the cases of measuring blood flow to the feet and lower limbs of people with diabetes.

Despite its importance, there is no ideal way to measure blood flow noninvasively and inexpensively. Current methods like blood pressure and 2D ultrasound (i.e., spectral Doppler) provide only surrogate metrics rather than the desired volumetric flow or have substantial limitations and are prone to errors. True flow measurements with 2D ultrasound are rarely used clinically due to reliability issues and cumbersome implementation. In addition, results often vary considerably between facilities and operators. Measurements from an experienced ultrasound technologist might differ significantly from those of a less experienced one.

“Right now, we just don’t have anything better to quantify blood flow,” said study lead author Oliver D. Kripfgans, Ph.D., associate professor of radiology from the Department of Radiology at Michigan Medicine in Ann Arbor, Michigan.

Dr. Kripfgans and his Michigan Medicine colleagues J. Brian Fowlkes, Ph.D., Stephen Z. Pinter, Ph.D., and Jonathan M. Rubin, M.D., Ph.D., have spent years developing and studying a 3D approach for quantitatively measuring blood flow. For the new study, he and his colleagues, along with other volunteers involved in the Quantitative Imaging Biomarkers Alliance (QIBA), tested this 3D approach on three clinical scanners using a custom flow phantom, a device that mimics blood flow in humans. They used seven different laboratories and manipulated the testing conditions by changing flow rate, imaging depth and other parameters for a total of eight distinct testing conditions.

The results showed that blood volume flow estimated by 3D color-flow ultrasound was accurate and reproducible among the seven laboratories.

“We had less than 10% error or variation,” Dr. Kripfgans said. “For some of the systems, we were down to only 3% to 5% difference between labs. These are fantastic results that show that, from a technology point of view, some systems could be ready to go to the clinic.”

Dr. Kripfgans credited the simplicity of the 3D approach, ease of data collection and elimination of assumptions plaguing other methods for minimizing the variation in results between users and systems. That simplicity, coupled with the availability of 3D on many existing ultrasound systems, is likely to hasten its arrival to clinical medicine, Dr. Kripfgans said.

“Once the technique becomes available commercially on scanners, clinical adoption will be much faster because then it’s not a research project anymore, it’s something that’s readily available, and after that it’s just a matter of time before it reaches the clinic,” he said.

QIBA, an alliance of researchers, health care professionals and industry representatives, was organized by the Radiological Society of North America in 2007 to improve current biomarkers and investigate new ones. Biomarkers are measurable indicators of the state of a person’s health.

The QIBA initiative includes collaboration to identify needs, barriers and solutions to create consistent, reliable, valid and achievable quantitative imaging results across imaging platforms, clinical sites, and time. QIBA aims to accelerate development and adoption of hardware and software standards to achieve accurate and reproducible quantitative results from imaging methods.

“Because of QIBA and this study I’m confident that this 3D ultrasound technology is on a path to the clinic,” Dr. Kripfgans said.

###

“Three-dimensional US for Quantification of Volumetric Blood Flow: Multisite Multisystem Results from within the Quantitative Imaging Biomarker Alliance.” Collaborating with Drs. Kripfgans, Fowlkes, Pinter and Rubin were Cristel Baiu, M.Sc., Matthew F. Bruce, Ph.D., Paul L. Carson, Ph.D., Shigao Chen, Ph.D., Todd N. Erpelding, Ph.D., Jing Gao, M.D., Mark E. Lockhart, M.D., M.P.H., Andy Milkowski, M.Sc., Nancy Obuchowski, Ph.D., Michelle L. Robbin, M.D., M.S., and James A. Zagzebski, Ph.D.

Radiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on ultrasound, visit RadiologyInfo.org.